General practitioners throughout Germany were invited to participate in two open-label, noncomparative PMS studies, performed in accordance with the guidelines of German Drug Law (AMG). The reporting ...

Concomitant therapy with the following medications was prohibited: other ARBs, angiotensin-converting enzyme (ACE) inhibitors, β-adrenergic antagonists, calcium-channel blockers, any other ...

The benefits of valsartan (Val)/hydrochlorothiazide (HCTZ) combination as initial treatment for hypertension were evaluated in a post hoc analysis of an 8-week, double-blind, placebo-controlled, ...

Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/160 mg/25 mg, 30-count bottles, lot. Nos. 21x006, expiration 11/2018 and 21x007, expiration 2/2019.

Although the patent on valsartan (Diovan, Novartis) expired last Friday, a generic version of the popular antihypertensive drug has yet to make it to market. By contrast, a generic version of Diovan ...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals USA today confirmed a voluntary recall to the consumer / user level of 29 lots of single and 51 lots of combination valsartan medicines ...

A generic drug company has recalled three commonly prescribed blood pressure medications over concerns they could include small amounts of a cancer-causing impurity. The recalled drugs all include the ...

Several common drugs that contain valsartan, used to treat high blood pressure and heart failure, were recalled in the United States on Friday due to an "impurity" in the drug that poses a potential ...

Aurobindo Pharma USA, Inc. is recalling80 lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP due totrace amounts of an unexpected impurity. This impurity ...

Several common drugs that contain valsartan, used to treat high blood pressure and heart failure, have been recalled in the United States due to an "impurity" in the drug that poses a potential cancer ...

The main purpose of the two open, non-comparative PMS studies reported here was to extend the knowledge base of the efficacy and tolerability of once-daily valsartan (trial 1) and the fixed ...